HEALTHCARE FACILITY TRANSFER FORM

Affix patient labels here.

Use this form for all transfers to an admitting healthcare facility.

Patient Name (Last, First):									
Date of Birth:	MRN:	Transfer Date:							
Receiving Facility Name:									
Contact Name: Contact Phone:									
Sending Facility Name:									
Contact Name:	ct Name: Contact Phone:								
PRECAUTIONS									
Patient currently on precautions? If yes, check all that apply: □ Yes □ No □ Airborne □ Contact □ Droplet □ Enhanced Standard*									
Personal protective equipment (PPE) to consider at receiving facility*:									
☐ Gloves ☐ Gown	☐ Mask	☐ N95/PAPR ☐ Eye Protection							
*Long-term care facilities may implement Enhanced Standard Precautions (PDF) (www.cdph.ca.gov/Programs/CHCQ/LCP/CDPH%20Document%20Library/AFL-19-22.pdf) for patients with MDRO or risk factors for transmission, i.e., gown and glove use for high-contact care activities; such patients may be on Contact precautions in acute care settings. ORGANISMS (Include copy of lab results with organism ID and antimicrobial susceptibilities.)									
Patient has multidrug-resistant	organism (MDRO) or other lab r	esults requiring pre	ecautions?						
☐ Yes (record organism(s), specimen source, collection date) ☐ No ☐ Exposed to MDRO/other (record organism(s) and last date(s) of exposure if known)									
Orgai	Carbapenemase (if applicable)**	Source	Date						
☐ Candida auris (C. auris)									
☐ Clostridiodes difficile (C. diff) ☐ Acinetobacter, multidrug-resistant (e.g., CRAB**)									
☐ Carbapenem-resistant Enterobacterales (CRE**) ☐ Pseudomonas aeruginosa, multidrug-resistant (e.g., CRPA**)									
☐ Extended-spectrum beta-lactamase (ESBL)-producer									
☐ Methicillin-resistant Staphylococcus aureus (MRSA)									
□ Vancomycin-resistant Enterococcus (VRE)									
☐ No organism identified (e.g., molecular screening test**)									
☐ Other, specify:									
(e.g., SARS-CoV-2 (COVID-19), lice, scabies, disseminated									
I shingles (<i>Hernes zoster</i>), noroviri	is intluenza tuberculosis)	1	l						

^{**} Note specific carbapenemase(s) (e.g., NDM, KPC, OXA-23) if known

Affix patient labels here.

CLINICAL STATUS							
Patient has any of the	following	symptoms or c	linical status?				
\square Yes \square No							
If yes, check all that currently apply: ☐ Cough/uncontrolled respiratory secretions ☐ Vomiting ☐ Acute diarrhea or incontinent stool § ☐ Incontinent of urine §		 □ Total dependence for activities of daily living § □ Rash consistent with an infectious process (e.g., vesicular) □ Draining wounds § □ Other uncontained bodily fluid / drainage 					
ANTIBIOTICS/ANTIFUNG	SALS						
Patient is currently on	antibiotics	/systemic anti	fungals?				
\square Yes \square No							
If yes, specify:							
Antibiotic/Antifungal	Dose	Frequency	Indication	Start Date	Stop Date		
DEVICES §		<u> </u>		<u> </u>			
Patient currently has a	ny of the f	ollowing devic	es?				
	rently ann	lv.					
If yes, check all that currently apply: ☐ Central line/PICC, Date inserted:			☐ Wound VAC☐ Tracheostomy				
☐ Hemodialysis catheter			☐ Urinary catheter, Date inserted:				
☐ Fecal management system			☐ Suprapubic catheter				
\square Percutaneous gastrostomy feeding tube		☐ Mechanical ventilation					
IMMUNIZATION STATUS	S						
(Attach immunization	record, if a	_	occal, Influenza, COVID-	19) in the past	12 months?		
☐ Yes (specify below)	□ No						
Vaccine				Date(s)			

[§] Risk factors for MDRO transmission per <u>Enhanced Standard Precautions</u> (PDF) (www.cdph.ca.gov/Programs/CHCQ/LCP/CDPH%20Document%20Library/AFL-19-22.pdf)